Characteristics of US adults with the metabolic syndrome and therapeutic implications

Jacobson, Terry A.; Case, Christopher; Roberts, Seth; Buckley, A; Murtaugh, Kathleen; Sung, Jennifer; Gause, Douglas; Varas, Cristina; Ballantyne, Christie M.

doi:10.1111/j.1462-8902.2004.00354.x

Cited by 35 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, HDL-C level is significantly higher in our study than in these studies. The frequency of low HDL component of MS is not higher in Turkish population than those in the USA population (Jacobson et al, 2004). In the past few years, several studies have consistently provided higher concentrations of HDL-C in Turkish adults that is similar to our results (Ilerigelen et al, 2005;Uzunlulu et al, 2005).…”

Section: Discussionsupporting

confidence: 91%

Prevalence of the metabolic syndrome among Turkish adults

Oğuz²,

et al. 2006

View full text Add to dashboard Cite

Objective: To determine prevalence of the metabolic syndrome (MS) in a sample representing Turkish population using United States Adult Treatment Panel-3 guidelines. Design: The study included random samples from both urban and rural populations in the seven geographical regions of Turkey. The population for this analysis were 2108 men (1372 in urban and 736 in rural areas) and 2151 women (1423 in urban and 728 in rural areas) with a mean age of 40.9714.9 years (range 20-90). Results: The prevalence of the MS diagnosed using the Adult Treatment Panel III criteria was 33.9% (1442 of 4259) and differed significantly in men (28%) and women (39.6%). The prevalence of syndrome increased with age in men, from 10.7% in subjects aged 20-29 years to 49% in those aged over 70 years. The prevalence increased with age in women, from 9.6% in subjects aged 20-29 years to 74.6% in those aged 60-69 years, and decreased to 68.6% in those over 70 years of age. The prevalence of the syndrome was similar in urban (33.8%) and rural (33.9%) population. We found 26.8, 26.4, 19.3, 10.9 and 3.6% of the population had at least 1, 2, 3, 4 or 5 components, respectively. We found 57.2, 32.3 and 10.6% of the subjects with MS had 3, 4 and 5 components, respectively.

show abstract

Section: Discussionsupporting

confidence: 91%

Prevalence of the metabolic syndrome among Turkish adults

Oğuz²,

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Analysis of the third National Health and Nutrition Examination Survey data from the adult general population also showed elevated non-HDL in more than 75% of patients with MS. Of those with TG level of greater than 200 mg/dL, more than 75% had non-HDL above NECP ATP III recommended levels. 34 This implies that when non-HDL is used as the therapeutic target, patients should be treated more aggressively to reach the goal. Alternatively, target threshold should be redefined based on estimated normal upper limit of all components in non-HDL including LDL, VLDL, and IDL cholesterols.…”

Section: Discussionmentioning

confidence: 99%

Non-High-Density Lipoprotein Cholesterol in Patients with Metabolic Syndrome

Huang

Parish

Mansi

et al. 2008

Journal of Investigative Medicine

View full text Add to dashboard Cite

show abstract

“…total cholesterol -HDL-C) above targets recommended by clinical guidelines. 14 Together, these data suggest that reduction in this excess coronary risk requires additional therapeutic intervention. Data from a recent meta-analysis 15 reinforce this viewpoint.…”

Section: Reduction Of Cardiovascular Risk Beyond Statin Therapymentioning

confidence: 95%

The role of fenofibrate in clinical practice

Zambón

Cusi

2007

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

PPARα is critical to lipid metabolism in the liver. Recent findings which showed that pioglitazone, a PPARγ agonist with weak PPARα activity, improved fatty liver disease in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome or type 2 diabetes have prompted interest in whether more potent PPARα agonists, such as fenofibrate, may have a role in the management of non-alcoholic fatty liver disease (NAFLD). The combination of fenofibrate and a statin is well tolerated, with no apparent increase in the risk of myopathy, unlike gemfibrozil-statin combination therapy.In overview, the available evidence indicates that the combination of fenofibrate with a statin is a useful approach for optimising reduction in the risk of cardiovascular disease in patients with type 2 diabetes and metabolic syndrome, as well as delaying the progression of diabetes-related microvascular complications. Data are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) study to evaluate the outcome benefits of this approach. Diabetes Vasc Dis Res 2007;4(suppl 3):S15-S20

show abstract

Characteristics of US adults with the metabolic syndrome and therapeutic implications

Cited by 35 publications

References 34 publications

Prevalence of the metabolic syndrome among Turkish adults

Prevalence of the metabolic syndrome among Turkish adults

Non-High-Density Lipoprotein Cholesterol in Patients with Metabolic Syndrome

The role of fenofibrate in clinical practice

Contact Info

Product

Resources

About